Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 10.20
+0.17 (1.69%)
May 7, 2026, 4:08 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 9.71 billion as of May 7, 2026. Its market cap has increased by 70.23% in one year.
Market Cap
9.71B
Enterprise Value
8.35B
Revenue
630.11M
Ranking
n/a
PE Ratio
n/a
Stock Price
10.20
Market Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 9.71B, a decrease of -19.78%. That is a compound annual growth rate of -3.38%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 6, 2026 | 9.71B | 2.35% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascentage Pharma Group International | 15.55B |
| CStone Pharmaceuticals | 13.70B |
| Everest Medicines | 11.86B |
| CARsgen Therapeutics Holdings | 11.84B |
| HBM Holdings | 10.75B |
| Shanghai Haohai Biological Technology | 9.32B |
| Lepu Biopharma | 9.27B |
| Abbisko Cayman | 8.67B |